Inhibition of DNA synthesis by cytosine arabinoside: Relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease
- 1 August 1984
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 20 (8) , 1061-1068
- https://doi.org/10.1016/0277-5379(84)90109-3
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Therapy of Secondary Acute Nonlymphocytic Leukemia with CytarabineNew England Journal of Medicine, 1983
- The treatment of acute myelocytic leukemia in patients 30 years of age and youngerAmerican Journal of Hematology, 1982
- Treatment of acute myelocytic leukemia: a study by cancer and leukemia group BBlood, 1981
- Evaluation of in vitro predictive assays for acute myelocytic leukemiaAnnals of Hematology, 1980
- High dose cytosine arabinoside (HDARAC) in refractory acute leukemiaCancer, 1979
- Inhibition by arabinosylcytosine of DNA synthesis in bone marrows of relapsed AML patientsPublished by Elsevier ,1979
- Treatment of acute nonlymphocytic leukemia: use of anthracycline- cytosine arabinoside induction therapy and comparison of two maintenance regimensBlood, 1979
- Remission induction in acute nonlymphocytic leukemia: Comparison of a seven‐day and ten‐day infusion of cytosine arabinoside in combination with adriamycinMedical and Pediatric Oncology, 1979
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976
- The metabolism of cytosine arabinoside as a predictive test for clinical response to the drug in acute myeloid leukaemiaPublished by Elsevier ,1976